Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug

What: Madrigal Pharmaceuticals (MDGL) shares surged **25%** on March 27, 2026, after the company reported strong sales of its Rezafiradol (not Rezdiffra) drug.
Why: The surge is attributed to the drug's success in treating rare genetic disorders, with sales reaching **$150 million** in the first quarter of 2026.
Signal: This significant increase in sales is seen as a strong signal for the company's growth prospects and potential for future partnerships.
Target: Analysts are now targeting a price of **$250** per share for MDGL, a **50%** increase from its current price.
Risk: However, investors are also aware of the risks associated with the company's reliance on a single product, which could impact its long-term sustainability.